Literature DB >> 18467511

Intersession variability in single-breath diffusing capacity in diabetics without overt lung disease.

Michael B Drummond1, Pamela F Schwartz, William T Duggan, John G Teeter, Richard J Riese, Richard C Ahrens, Robert O Crapo, Richard D England, Neil R Macintyre, Robert L Jensen, Robert A Wise.   

Abstract

RATIONALE: American Thoracic Society guidelines state that a 10% or greater intersession change in diffusing capacity of the lung (DL(CO)) should be considered clinically significant. However, little is known about the short-term intersession variability in DL(CO) in untrained subjects or how variability is affected by rigorous external quality control.
OBJECTIVES: To characterize the intersession variability of DL(CO) and the effect of different quality control methods in untrained individuals without significant lung disease.
METHODS: Data were pooled from the comparator arms of 14 preregistration trials of inhaled insulin that included nonsmoking diabetic patients without significant lung disease. A total of 699 participants performed repeated DL(CO) measurements using a highly standardized technique. A total of 948 participants performed repeated measurements using routine clinical testing.
MEASUREMENTS AND MAIN RESULTS: The mean intersession absolute change in DL(CO) using the highly standardized method was 1.45 ml/minute/mm Hg (5.64%) compared with 2.49 ml/minute/mm Hg (9.52%) in the routine testing group (P < 0.0001 for both absolute and percent difference). The variability in absolute intersession change in DL(CO) increased with increasing baseline DL(CO) values, whereas the absolute percentage of intersession change was stable across baseline values. Depending on the method, 15.5 to 35.5% of participants had an intersession change of 10% or greater. A 20% or greater threshold would reduce this percentage of patients to 1 to 10%.
CONCLUSIONS: Intersession variability in DL(CO) measurement is dependent on the method of testing used and baseline DL(CO). Using a more liberal threshold to define meaningful intersession change may reduce the misclassification of normal variation as abnormal change.

Entities:  

Mesh:

Year:  2008        PMID: 18467511      PMCID: PMC2542422          DOI: 10.1164/rccm.200801-090OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  32 in total

1.  Predictors of longitudinal change in diffusing capacity over 8 years.

Authors:  D L Sherrill; P L Enright; W T Kaltenborn; M D Lebowitz
Journal:  Am J Respir Crit Care Med       Date:  1999-12       Impact factor: 21.405

Review 2.  Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment.

Authors:  S M Proudman; W M Stevens; J Sahhar; D Celermajer
Journal:  Intern Med J       Date:  2007-07       Impact factor: 2.048

3.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

4.  Intraindividual variability in serial measurements of DLCO and alveolar volume over one year in eight healthy subjects using three independent measuring systems.

Authors:  E H Hathaway; D P Tashkin; M S Simmons
Journal:  Am Rev Respir Dis       Date:  1989-12

5.  Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial.

Authors:  Ralph A DeFronzo; Richard M Bergenstal; William T Cefalu; John Pullman; Sam Lerman; Bruce W Bode; Lawrence S Phillips
Journal:  Diabetes Care       Date:  2005-08       Impact factor: 19.112

6.  Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes.

Authors:  Jay S Skyler; Lois Jovanovic; Sol Klioze; Joann Reis; William Duggan
Journal:  Diabetes Care       Date:  2007-03       Impact factor: 19.112

7.  Randomized study to characterize glycemic control and short-term pulmonary function in patients with type 1 diabetes receiving inhaled human insulin (exubera).

Authors:  Paul Norwood; Richard Dumas; William Cefalu; Jean-Francois Yale; Richard England; Richard Riese; John Teeter
Journal:  J Clin Endocrinol Metab       Date:  2006-09-26       Impact factor: 5.958

8.  Inhaled human insulin treatment in patients with type 2 diabetes mellitus.

Authors:  W T Cefalu; J S Skyler; I A Kourides; W H Landschulz; C C Balagtas; S Cheng; R A Gelfand
Journal:  Ann Intern Med       Date:  2001-02-06       Impact factor: 25.391

9.  Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial.

Authors:  Priscilla A Hollander; Lawrence Blonde; Richard Rowe; Adi E Mehta; Joseph L Milburn; Kenneth S Hershon; Jean-Louis Chiasson; Seymour R Levin
Journal:  Diabetes Care       Date:  2004-10       Impact factor: 19.112

10.  Lung volumes in healthy nonsmoking adults.

Authors:  R O Crapo; A H Morris; P D Clayton; C R Nixon
Journal:  Bull Eur Physiopathol Respir       Date:  1982 May-Jun
View more
  3 in total

1.  Interpretation of pulmonary function test: issues and controversies.

Authors:  Cristine E Berry; Robert A Wise
Journal:  Clin Rev Allergy Immunol       Date:  2009-03-21       Impact factor: 8.667

Review 2.  Interstitial Pneumonia With Autoimmune Features: An Emerging Challenge at the Intersection of Rheumatology and Pulmonology.

Authors:  Erin M Wilfong; Robert J Lentz; Adam Guttentag; James J Tolle; Joyce E Johnson; Jonathan A Kropski; Peggy L Kendall; Timothy S Blackwell; Leslie J Crofford
Journal:  Arthritis Rheumatol       Date:  2018-10-27       Impact factor: 10.995

3.  CT quantification of the heterogeneity of fibrosis boundaries in idiopathic pulmonary fibrosis.

Authors:  Junghoan Park; Julip Jung; Soon Ho Yoon; Helen Hong; Hyungjin Kim; Heekyung Kim; Jeong-Hwa Yoon; Jin Mo Goo
Journal:  Eur Radiol       Date:  2021-01-13       Impact factor: 7.034

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.